ArticleMarine drugs2014
Intestinal absorption of fucoidan extracted from the brown seaweed, Cladosiphon okamuranus.
Article in Marine drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 151 citations in OpenAlex.
- Brown Seaweed Food Supplementation: Effects on Allergy and Inflammation and Its Consequences.Nutrients · 2021Pooled it
- Effects of Ingesting Fucoidan Derived fromMarine drugs · 2021Trial
- The Effect of Undaria pinnatifida Fucoidan on the Pharmacokinetics of Letrozole and Tamoxifen in Patients With Breast Cancer.Integrative cancer therapies · 2018Trial
- Fucoidans as multifunctional marine polysaccharide platforms: From nutritional supplements to advanced drug delivery for cancer therapy.International journal of pharmaceutics: X · 2026Review
- Fucoidan Oligosaccharides fromMarine drugs · 2026Article
- Marine Bioactives in Liver Aging: Mechanistic Insights and Translational Potential.Marine drugs · 2026Review
- Orally Administered Rhamnan Sulfate fromMarine drugs · 2026Article
- Selective antimicrobial potential of fucoidans against the pathogenFrontiers in microbiology · 2026Article
- Secret heroes of the sea: brown macroalgae and their bioactive powers-a narrative review.Frontiers in nutrition · 2026Review
- Anti-Inflammatory and Neuroprotective Effects ofMarine drugs · 2025Review
- Article
- Absorption Patterns of Fucoidan Oligosaccharides fromFoods (Basel, Switzerland) · 2025Article
- Fucoidan fromFrontiers in pharmacology · 2025Article
- Fucoidan as a therapeutic agent for ulcerative colitis: mechanisms of action and modulation of the gut microbiota.Frontiers in cellular and infection microbiology · 2025Review
- Review
- Maintenance of homeostasis by TLR4 ligands.Frontiers in immunology · 2024Review
- Novel Fucoidan Pharmaceutical Formulations and Their Potential Application in Oncology-A Review.Polymers · 2023Review
- Ten Years of Research on Fucoidan and Cancer: Focus on Its Antiangiogenic and Antimetastatic Effects.Marine drugs · 2023Review
- Seaweed-Derived Sulfated Polysaccharides; The New Age Chemopreventives: A Comprehensive Review.Cancers · 2023Review
- A Review on Fucoidan Structure, Extraction Techniques, and Its Role as an Immunomodulatory Agent.Marine drugs · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to examine the absorption of fucoidan through the intestinal tract. Fucoidan (0.1, 0.5, 1.0, 1.5 and 2.0 mg/mL) was added to Transwell inserts containing Caco-2 cells. The transport of fucoidan across Caco-2 cells increased in a dose-dependent manner up to 1.0 mg/mL. It reached a maximum after 1 h and then rapidly decreased. In another experiment, rats were fed standard chow containing 2% fucoidan for one or two weeks. Immunohistochemical staining revealed that fucoidan accumulated in jejunal epithelial cells, mononuclear cells in the jejunal lamina propria and sinusoidal non-parenchymal cells in the liver. Since we previously speculated that nitrosamine may enhance the intestinal absorption of fucoidan, its absorption was estimated in rats administered N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in their drinking water. Rats were fed 0.2% fucoidan chow (BBN + 0.2% fucoidan rats), 2% fucoidan chow (BBN + 2% fucoidan rats) and standard chow for eight weeks. The uptake of fucoidan through the intestinal tract seemed to be low, but was measurable by our ELISA method. Fucoidan-positive cells were abundant in the small intestinal mucosa of BBN + 2% fucoidan rats. Most fucoidan-positive cells also stained positive for ED1, suggesting that fucoidan was incorporated into intestinal macrophages. The uptake of fucoidan by Kupffer cells was observed in the livers of BBN + 2% fucoidan rats. In conclusion, the absorption of fucoidan through the small intestine was demonstrated both in vivo and in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.